Literature DB >> 21406980

Antiretroviral therapy: a promising HIV prevention strategy?

Wafaa M El-Sadr1, Megan Affrunti, Theresa Gamble, Allison Zerbe.   

Abstract

The use of antiretroviral therapy (ART) has been associated with significant improvement in morbidity and survival of persons living with HIV. In addition, recently, there has also been intense interest in the potential impact of ART on HIV transmission and consequently on the trajectory of the HIV epidemic globally. Evidence from mathematical modeling analyses and observational and ecological studies supports the potential for ART as prevention. However, definitive data from clinical trials are awaited. In the United States, the feasibility and potential of using ART as a prevention strategy presents particular challenges: the large number of individuals with undiagnosed HIV; the predominance of disenfranchised individuals affected by the epidemic; evidence of delay in engagement in HIV care after diagnosis with attendant late initiation of ART; and difficulties with consistent long-term adherence to ART and concerns regarding long-term risk-behavior change. Thus, for this novel effort to succeed, a multidimensional approach is necessary that must include policy changes, social mobilization, and improved access to clinical and supportive services for persons living with HIV, with a particular focus on the unique needs of at-risk populations, combined with engagement of all cadres of health care providers and community constituencies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21406980      PMCID: PMC3074403          DOI: 10.1097/QAI.0b013e3181fbca6e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  54 in total

Review 1.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

Authors:  J X Velasco-Hernandez; H B Gershengorn; S M Blower
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

2.  Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda.

Authors:  Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

3.  Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months.

Authors:  Susan Cu-Uvin; Brad Snyder; Joseph I Harwell; Joseph Hogan; Carla Chibwesha; Dawn Hanley; Jessica Ingersoll; Jaclynn Kurpewski; Kenneth H Mayer; Angela M Caliendo
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

5.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

6.  Estimation of HIV incidence in the United States.

Authors:  H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

7.  Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions.

Authors:  Steffanie A Strathdee; Jamila K Stockman
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

8.  Persons tested for HIV--United States, 2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-08-08       Impact factor: 17.586

Review 9.  Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.

Authors:  David R Bangsberg
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

10.  Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies.

Authors:  Josè Ramòn Fiore; Barbara Suligoi; Annalisa Saracino; Mariantonietta Di Stefano; Roberto Bugarini; Achiropita Lepera; Anna Favia; Laura Monno; Gioacchino Angarano; Giuseppe Pastore
Journal:  AIDS       Date:  2003-10-17       Impact factor: 4.177

View more
  15 in total

1.  Latent class profiles of internalizing and externalizing psychosocial health indicators are differentially associated with sexual transmission risk: Findings from the CFAR network of integrated clinical systems (CNICS) cohort study of HIV-infected men engaged in primary care in the United States.

Authors:  Matthew J Mimiaga; Katie Biello; Sari L Reisner; Heidi M Crane; Johannes Wilson; Chris Grasso; Mari M Kitahata; Wm Christopher Mathews; Kenneth H Mayer; Steven A Safren
Journal:  Health Psychol       Date:  2015-02-02       Impact factor: 4.267

Review 2.  HIV transmission rate modeling: a primer, review, and extension.

Authors:  Steven D Pinkerton
Journal:  AIDS Behav       Date:  2012-05

3.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

4.  Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.

Authors:  Jason R Andrews; Robin Wood; Linda-Gail Bekker; Keren Middelkoop; Rochelle P Walensky
Journal:  J Infect Dis       Date:  2012-06-18       Impact factor: 5.226

5.  Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who's in and who's out?

Authors:  Ellen M Tedaldi; James T Richardson; Rachel Debes; Benjamin Young; Joan S Chmiel; Marcus D Durham; John T Brooks; Kate Buchacz
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-02-03

6.  Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort.

Authors:  Matthew J Mimiaga; Sari L Reisner; Chris Grasso; Heidi M Crane; Steven A Safren; Mari M Kitahata; Joseph E Schumacher; W Christopher Mathews; Kenneth H Mayer
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

7.  Clinician practices and attitudes regarding early antiretroviral therapy in the United States.

Authors:  Ann E Kurth; Kenneth Mayer; Geetha Beauchamp; Laura McKinstry; Jennifer Farrior; Kate Buchacz; Deborah Donnell; Bernard Branson; Wafaa El-Sadr
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

8.  The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model.

Authors:  Bruno Ventelou; Yves Arrighi; Robert Greener; Erik Lamontagne; Patrizia Carrieri; Jean-Paul Moatti
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

9.  Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs.

Authors:  Bradley G Wagner; Sally Blower
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

10.  mHealth for HIV Treatment & Prevention: A Systematic Review of the Literature.

Authors:  Caricia Catalani; William Philbrick; Hamish Fraser; Patricia Mechael; Dennis M Israelski
Journal:  Open AIDS J       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.